<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439721</url>
  </required_header>
  <id_info>
    <org_study_id>PG-γδT-001</org_study_id>
    <nct_id>NCT04439721</nct_id>
  </id_info>
  <brief_title>γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse</brief_title>
  <acronym>γδT</acronym>
  <official_title>Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia&#xD;
      Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      γδT cells belong to the innate immune system and have a powerful anti-tumor effect. Leukemia&#xD;
      patients transplanted with allogeneic hematopoietic stem cells have an important role in&#xD;
      controlling leukemia recurrence. Although adoptive immunotherapy using in vitro expanded γδT&#xD;
      cells has achieved significant results in patients with solid tumors, infusion of donor γδT&#xD;
      cells in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation to&#xD;
      prevent leukemia recurrence has not been reported. . This clinical study intends to initially&#xD;
      observe the safety and effectiveness of donor γδT cell infusion to prevent&#xD;
      recurrence/refractory leukemia salvage allogeneic hematopoietic stem cell transplantation to&#xD;
      further improve the transplantation effect of these patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the dose limiting toxicity (DLT)</measure>
    <time_frame>4 weeks after γδT infusion</time_frame>
    <description>Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 5 and the number of patients experiencing DLT will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of serious adverse events (SAEs)</measure>
    <time_frame>4 weeks after γδT infusion</time_frame>
    <description>The incidence of serious adverse events (SAEs) after γδT infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival time(DFS)</measure>
    <time_frame>about 2 years after γδT infusion</time_frame>
    <description>γδT cell infusion treatment of CR/CRi patients from the beginning of γδT cell infusion treatment to the first disease recurrence or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>about 2 years after γδT infusion</time_frame>
    <description>The time from the subject receiving γδT cell infusion treatment to death (for any reason)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission after administration (DOR)</measure>
    <time_frame>about 2 years after γδT infusion</time_frame>
    <description>γδT cell infusion treatment has not reached CR/CRi before the treatment, the time from the first assessment of CR/CRi after administration to the first assessment of disease recurrence or progression or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Leukemia, B-cell</condition>
  <arm_group>
    <arm_group_label>γδT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>γδT Cell infusion agent</intervention_name>
    <description>γδT</description>
    <arm_group_label>γδT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute leukemia patients undergoing salvage allogeneic hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Age 10-65,Any gender&#xD;
&#xD;
          -  Expected lifetime&gt;3months&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  DSA Negative&#xD;
&#xD;
          -  Successful granulocyte implantation&#xD;
&#xD;
          -  Liver and kidney function, heart and lung function meet the following&#xD;
             requirements:①Creatinine≤1.5 ULN；②ALT/AST ≤5 ULN； ③Baseline oxygen saturation≥92%；&#xD;
             ④Left ventricular ejection fraction≥50%&#xD;
&#xD;
          -  Female subjects with fertility who had a negative pregnancy test within 48 hours&#xD;
             before the infusion and were not breastfeeding; all subjects with fertility potential&#xD;
             before enrolling in the study and throughout the study period until the last infusion&#xD;
             Within 3 months, take adequate contraceptive measures&#xD;
&#xD;
          -  Signing informed consent patients must be able to understand and be willing to&#xD;
             participate in this study, and sign informed consent at the same time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Donor HBsAg or HBcAb positive and HBV DNA titer test is not within the normal&#xD;
             reference value; donor or patient HCV antibody positive and peripheral blood HCV RNA&#xD;
             positive; donor or patient HIV antibody positive; donor syphilis test positive&#xD;
&#xD;
          -  Active central nervous system disease&#xD;
&#xD;
          -  BMI index&gt;35&#xD;
&#xD;
          -  Allergic to DMSO&#xD;
&#xD;
          -  Graft-versus-host disease&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Systemic steroid therapy is required during cell infusion or cell collection, or there&#xD;
             are conditions that researchers believe may require steroid therapy during blood&#xD;
             collection or during infusion. In addition to cell collection or infusion, steroids&#xD;
             for disease treatment are allowed, and inhaled steroids or hydrocortisone are also&#xD;
             allowed for physiological replacement therapy in patients with adrenal insufficiency&#xD;
&#xD;
          -  Participated in another clinical trial within 4 weeks before enrolling in the study,&#xD;
             or intend to participate in another clinical trial throughout the study&#xD;
&#xD;
          -  According to the judgment of the investigator, it does not meet the situation of cell&#xD;
             preparation&#xD;
&#xD;
          -  Circumstances considered by other researchers to be inappropriate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suning Chen, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology，The First Affiliaated Hospital Of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suning Chen, Ph.D</last_name>
    <phone>13814881746</phone>
    <email>chensuning@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaofei Yang, Ph.D</last_name>
    <phone>18962156841</phone>
    <email>yangxiaofei1977@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>No.188 Shizi Street</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofei Yang, Ph.D</last_name>
      <phone>18962156841</phone>
      <email>yangxiaofei1977@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>γδT</keyword>
  <keyword>leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

